Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma

Table 1 Baseline characteristics of all patients

Characteristic	N	Percentage
Sex
Male	254	80.6
Female	61	19.4
Comorbidities
Hypertension	105	33.3
Diabetes mellitus	46	14.6
Coronary heart disease	37	11.7
Smoking history
Yes	216	68.6
No	99	31.4
ECOG PS
0–1	285	90.5
2	30	9.5
Histology
Adenocarcinoma	135	42.9
Squamous cell carcinoma	117	37.1
Small cell carcinoma	45	14.3
Large cell carcinoma	6	1.9
Unknown	12	3.8
Clinical stage
I-II	7	2.2
III	44	14.0
IV	264	83.8
Metastasis site
Brain	54	17.1
Bone	71	22.5
Liver	33	10.5
Mutational status
EGFR	59	18.7
ALK	15	4.8
Negative	79	25.1
Unknown	162	51.4
PD-L1 expression levels
<1%	109	34.6
1–49%	77	24.4
≥ 50%	67	21.3
Unknown	62	19.7
Corticosteroid interference
Yes	13	4.1
No	302	95.9
Abx treatment
Yes(≥7 days)	43	13.7
Yes(<7 days)	48	15.2
No	224	71.1
Lines of therapy
1	165	52.4
2	150	47.6
Immune drugs
atezolizumab	20	6.3
durvalumab	16	5.1
sintilimab	108	34.3
pembrolizumab	38	12.1
camrelizumab	46	14.6
tislelizumab	59	18.7
toripalimab	28	8.9

ISSN: 1471-2407